Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM
NCT ID: NCT03925701
Last Updated: 2019-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
120 participants
INTERVENTIONAL
2019-04-01
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
NCT03253562
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
NCT07077525
Anti-diabetic Drugs and Fatty Liver Management
NCT05041673
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
NCT04485845
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
NCT05429554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vildagliptin
vildagliptin 50 mg twice daily
Vildagliptin
vildagliptin twice daily
vildagliptin\metformin
vildagliptin\\metformin twice daily
vildagliptin\metformin
vildagliptin\\metformin twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vildagliptin
vildagliptin twice daily
vildagliptin\metformin
vildagliptin\\metformin twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Child score more than 6.
* renal impairment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aya G Moussa, Msc
Role: PRINCIPAL_INVESTIGATOR
Tanta University - Faculty of Pharmacy
Osama M Ibrahim, Prof
Role: PRINCIPAL_INVESTIGATOR
Prof of Clinical Pharmacy
Gamal Alazab, ass. Prof.
Role: STUDY_DIRECTOR
Prof of Clinical Pharmacy
Yasser Abdel Raouf, Ass Prof
Role: STUDY_CHAIR
Tanta University-Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sherief Abd-Elsalam
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
diabetes mellitus tanta
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.